

92 119. (Amended) A dosage amount of a pharmaceutical composition for treating [For use to treat] renal failure, cardiac insufficiency, hypertension and edema, said dosage amount comprising [the administration of] an effective amount of a diuretic and a sufficient amount of a form of hyaluronic acid selected from hyaluronic acid and its non-toxic salts and combinations thereof [and salts thereof and/or homologues, analogues, derivatives, complexes, esters, fragments and sub-units of hyaluronic acid] to facilitate the agent at a [the] site to be treated by the agents passing through the tissue [(including scar tissue)] through the cell membranes into the individual cells to be treated wherein the molecular weight of the form of hyaluronic acid is in the range of 150,000 to 750,000 daltons, and said amount of the form of hyaluronic acid is sufficient to provide a dosage greater than 10mg/70kg person.

3 120. (Amended) The dosage amount [For the use] of Claim 119 wherein the form of hyaluronic acid [and salts thereof and/or homologues, analogues, derivatives, complexes, esters, fragments and sub-units of hyaluronic acid is hyaluronic acid and/or salts thereof] is sodium hyaluronate. 2

4 121. (Amended) The dosage amount [For the use] of Claim 119 or [and] 120 wherein the diuretic is furosemide. 2 3

93 184. (Amended) A method of treating [For use to treat] renal failure, cardiac insufficiency, hypertension and edema, the method comprising the administration [the combination] of an effective amount of a diuretic and a sufficient amount of a form of hyaluronic acid selected from hyaluronic acid and its non-toxic salts and combinations thereof [and salts thereof and/or homologues, analogues, derivatives, complexes, esters, fragments and sub-units of hyaluronic acid] to facilitate the agent at a [the] site to be treated by the agents passing through the tissue [(including scar tissue)] through the cell membranes 73

into the individual cells to be treated wherein the molecular weight of the form of hyaluronic acid is in the range of 150,000 to 750,000 daltons, and said amount of the form of hyaluronic acid is sufficient to provide a dosage greater than 10mg/70kg person.

185. (Amended) The method [combination] of Claim 184 wherein the form of hyaluronic acid [and salts thereof and/or homologues, analogues, derivatives, complexes, esters, fragments and sub-units of hyaluronic acid is hyaluronic acid and/or salts thereof] is sodium hyaluronate.

186. (Amended) The method [combination] of Claim 184 or [and] 185 wherein the diuretic is furosemide.

REMARKS

Claims 11, 119-121 and 184-186 remain in the application. These claims prior to amendment stand rejected on various grounds under 35 USC §112, first and second paragraphs, 102(b) and 103, all of which Applicants respectfully traverse and believe are all overcome by the instant amendment, along with the enclosed Declarations.

In the interest of advancing the prosecution of the application, Applicants have amended the forms of hyaluronic acid in the claims to hyaluronic acid and its non-toxic salts. The term "salts" does not encompass a large number of components and, in fact, would be readily understood by a person skilled in the art. The salts are referring to salts of hyaluronic acid. These salts do not require undue experimentation. Furthermore, in respect of 35 U.S.C. §112, second paragraph, Applicant has removed the terminologies including "and/or" and "(including scar tissue)", thus overcoming the rejection under 35 U.S.C. §112, second paragraph. Furthermore, Applicants have rewritten said claims in